2019-002834-35 Randomized phase II study of panitumumab rechallenge followed by regorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients
Randomized phase II study of panitumumab rechallenge followed by regorafenib versus the reverse sequence in RAS and BRAF WILD-TYPE chemorefractory metastatic colorectal cancer patients